Cancer biomarker discovery via low molecular weight serum proteome profiling - Where is the tumor?

Proteomics - Clinical Applications

Volumn 1, Issue 12, 2007, Pages 1545-1558

  Davis, Michael T ^a   Auger, Paul ^a   Spahr, Chris ^a   Patterson, Scott D ^a  

^a AMGEN INC   (United States)

Author keywords

LMW peptidome; SELDI; Serum biomarkers

Indexed keywords

BIOLOGICAL MARKER; POLYPEPTIDE; PROTEINASE; PROTEOME; TUMOR MARKER;

ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; EX VIVO STUDY; HEMOSTASIS; HUMAN; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MOLECULAR WEIGHT; NANOANALYSIS; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THROMBOCYTE ACTIVATION;

EID: 38349116874     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200700141     Document Type: Article

References (85)

1. Cancer Facts and Figures 2006, American Cancer Society, Atlanta 2006.
2. Petricoin, E. F., Ardekani, A. A., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
3. Hutchen, T. W., Yip, T. T., New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. 1993, 7, 576-580.
4. Hortin, G. L., The MALDITOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52, 1223-1237.
5. Adam, B. L., Vlahou, A., Semmes, O. J., Wright, G. L., Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001, 1, 1264-1270.
6. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D. et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002, 62, 3609-3614.
7. Baggerly, K. A., Morris, J. S., Wang, J., Gold, D. et al., A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 2003, 3, 1667-1672.
8. Conrads, T. P., Fusaro, V. A., Ross, S., Johann, D. et al., High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 2004, 11, 163-178.
9. Diamandis, E. P., Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin. Chem. 2003, 49, 1272-1275.
10. Diamandis, E., Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J. Natl. Cancer Inst. 2004, 96, 353-356.
11. Baggerly, K. A., Edmonson, S. R., Morris, J. S., Coombes, K. R., High-resolution serum proteomic patterns for ovarian cancer detection. Endo. Relat. Cancer 2004, 11, 583-584.
12. Baggerly, K. A., Morris, J. S., Edmonson, S. R., Coombes, K. R., Signal in noise: Evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst. 2005, 97, 307-309.
13. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
14. Liotta, L. A., Ferrari, M., Petricoin, E., Clinical proteomics: Written in blood. Nature 2003, 425, 905-905.
15. Mehta, A. I., Ross, S., Lowenthal, M. S., Fusaro, V. et al., Biomarker amplification by serum carrier protein binding. Dis. Markers 2003-2004, 19, 1-10.
16. Lowenthal, M. S., Mehta, A. I., Frogale, K., Bandle, R. W. et al., Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin. Chem. 2005, 51, 1933-1945.
17. Gillette, M. A., Mani, D. R., Carr, S. A., Place of pattern in proteomic biomarker discovery. J. Proteome Res. 2005, 4, 1143-1154.
18. Cho, W. C. S., Yip, T. T. C., Yip, C., Yip, V. et al., Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 2004, 10, 43-52.
19. Koomen, J. M., Shih, L. N., Coombes, K. R., Li, D. et al., Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 2005, 11, 1110-1118.
20. Marshall, J., Kupchak, P., Zhu, W., Yantha, J. et al., Processing of serum proteins underlies the mass spectral finger-printing of myocardial infarction. J. Proteome Res. 2003, 2, 361-372.
21. Brummel, K. E., Butenas, S., Mann, K. G., An integrated study of fibrinogen during blood coagulation. J. Biol. Chem. 1999, 274, 22862-22870.
22. Orvisky, E., Drake, S. K., Martin, B. M., Abdel-Hamid, M. et al., Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics 2006, 6, 2895-2902.
23. Yu, J. K., Chen, Y. D., Zheng, S., An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 2004, 10, 3127-3131.
24. Engwegen, J. Y., Helgason, H. H., Cats, A., Harris, N. et al., Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 2006, 12, 1536-1544.
25. Bergen, H. R., III, Vasmatzis, G., Cliby, W. A., Johnson, K. L. et al., Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Dis. Markers 2003-2004, 19, 239-249.
26. Pang, R. T. K., Poon, T. C. W., Chan, K. C. A., Lee, N. L. S. et al., Serum proteomic fingerprints of adult patients with aevere acute respiratory syndrome. Clin. Chem. 2006, 52, 421-429.
27. Nomura, F., Tomonaga, T., Sogawa, K., Ohashi, T. et al., Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics 2004, 4, 1187-1194.
28. Licklider, L. J., Thoreen, C. C., Peng, J., Gygi, S. P., Automation of nanoscale microcapillary liquid chromatography-tandem mass spectrometry with a vented column. Anal. Chem. 2002, 74, 3076-3083.
29. Davis, M. T., Lee, T. D., Variable flow liquid chromatography -Tandem mass spectrometry. and the comprehensive analysis of complex protein digest mixtures. J. Am. Soc. Mass Spectrom. 1997, 8, 1059-1069.
30. McGinley, M. D., Davis, M. T., Robinson, J. H., Spahr, C. S. et al., A simplified device for protein identification by micro-capillary gradient liquid chromatography-tandem mass spectrometry. Electrophoresis 2000, 21, 1678-1684.
31. + ions of peptides. Side chain specific sequence ions. Int. J. Mass Spectrom. Ion Processes 1988, 86, 137-154.
32. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C. et al., Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 2005, 4, 972-981.
33. Theodorescu, D. W., Ross, S., Walden, M. M., Conaway, M. et al., Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lancet Oncol. 2006, 7, 230-240.
34. Liotta, L. A., Kohn, E. C., The microenvironment of the tumour-host interface. Nature 2001, 411, 375-379.
35. Grizzle, W. E. S., Semmes, O. J., Bigbee, W., Zhua, L. et al., The need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis. Cancer Inform. 2005, 1, 86-91.
36. Findeisen, P., Sismanidis, D., Riedl, M., Costina, V. et al., Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51, 2409-2411.
37. Tammen, H., Schulte, I., Hess, R., Menzel, C. et al., Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics 2005, 5, 3414-3422.
38. Rauch, B. H., Bretschneider, E., Braun, M., Schror, K., Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of Pro-MMP-2 to MMP-2: Role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ. Res. 2002, 90, 1122-1127.
39. Lafleur, M. A., Hollenberg, M. D., Atkinson, S. J., Knauper, V. et al., Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem. J. 2001, 357, 107-115.
40. Plow, E. F., Leukocyte elastase release during blood coagulation - A potential mechanism for activation of the alternative fibrinolytic pathway. J. Clin. Invest. 1982, 69, 564-572.
41. Jung, K., Laube, C., Lein, M., Lichtinhagen, R. et al., Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin. Chem. 1998, 44, 1060-1062.
42. Vermeulen, R., Lan, Q., Zhang, L., Gunn, L. et al., Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. PNAS 2005, 102, 17041-17046.
43. Zakhari, S., Alcohol and the cardiovascular system: Molecular mechanisms for beneficial and harmful action. Alcohol Health Res. World 1997, 21, 21-29.
44. Ying, W. L., Mobley, J. A., Evans, J. E., Carmody, J. F. et al., Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005, 5, 2927-2938.
45. Yip, T. T. C., Chan, J. W. M., Cho, W. C. S., Yip, T. T. et al., Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin. Chem. 2005, 51, 47-55.
46. Murakami, H., Yokoyama, A., Kondo, K., Nakanishi, S. et al., Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 8674-8679.
47. van Hensbergen, Y., Broxterman, H. J., Hanemaaijer, R., Jorna, A. S. et al., Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin. Cancer Res. 2002, 8, 3747-3754.
48. Yousef, G. M., Polymeris, M. E., Yacoub, G. M., Scorilas, A. et al., Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003, 63, 2223-2227.
49. Yousef, G. M., Polymeris, M. E., Grass, L., Soosaipillai, A. et al., Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003, 63, 3958-3965.
50. Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M. et al., Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 2003, 21, 1035-1043.
51. Kishi, T., Grass, L., Soosaipillai, A., Scorilas, A. et al., Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003, 63, 2771-2774.
52. Santin, A. D., Diamandis, E. P., Bellone, S., Soosaipillai, A. et al., Human kallikrein 6: A new potential serum biomarker for uterine serous papillary cancer. Clin. Cancer Res. 2005, 11, 3320-3325.
53. Tutton, M. G., George, M. L., Eccles, S. A., Burton, S. et al., Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int. J. Cancer 2003, 107, 541-550.
54. Hayasaka, A., Suzuki, N., Fujimoto, N., Iwama, E. et al., Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/ gelatinase B) in hepatocellular carcinoma. Hepatology 1996, 24, 1058-1062.
55. Ebert, M. P. A., Kruger, S., Fogeron, M.-L., Lamer, S. et al., Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 2005, 5, 1693-1704.
56. Hara, I. H. M., Yamanaka, K., Hara, S., Kamidono, S., Serum cathepsin D and its density in men with prostate cancer a now predictors of disease progression. Oncol. Rep. 2602, 9, 1379-1383.
57. Ishida, H., Murata, N., Tada, M., Okada, N. et al., Determining the levels of matrix metalloproteinase-9 in portal and peripheral blood is useful for predicting liver metastasis of colorectal cancer. Jpn. J. Clin. Oncol. 2003, 33, 186-191.
58. Yousef, G. M., Scorilas, A., Katsaros, D., Fracchioli, S. et al., Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 2003, 21, 3119-3126.
59. Yousef, G. M., Fracchioli, S., Scorilas, A., Borgono, C. A. et al., Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am. J. Clin. Pathot. 2003, 119, 346-355.
60. Diamandis, E. P., Borgono, C. A., Scorilas, A., Harbeck, N. et al., Human kallikrein 11: An indicator of favorable prognosis in ovarian cancer patients. Clin. Biochem. 2004, 37, 823-829.
61. Borgono, C. A., Diamandis, E. P., The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004, 4, 876-890.
62. Borgono, C. A., Michael, I. P., Diamandis, E. P., Human tissue kallikreins: Physiologic roles and applications in cancer. Mol. Cancer Res. 2004, 2, 257-280.
63. Rickles, F. R., Edwards, R. L., Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983, 62, 14-31.
64. Goldsmith, G. H., Hemostatic changes in patients with malignancy, Int. J. Hematol. 2001, 73, 151-156.
65. Toh, C. H., Dennis, M., Disseminated intravascular coagulation: old disease, new hope. BMJ 2003, 327, 974-977.
66. Bick, R. L., Disseminated intravascular coagulation: A review of etiology, pathophysiology, diagnosis, and management: Guidelines for care. Clin. Appl. Thromb. Hemost. 2002, 8, 1-31.
67. Franchini, M., Lippi, G., Manzato, F., Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb. J. 2006, 4, 4.
68. De Cicco, M., The prothrombotic state in cancer: Pathogenic mechanisms. Crit. Rev. Oncol./Hematol. 2004, 50, 187-196.
69. Cheng, A.-J., Chen, L.-C., Chien, K.-Y., Chen, Y.-J. et al., Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 2005, 51, 2236-2244.
70. Laronga, C. B., Watson, S, Gregory, P, Cazares, B. et al., SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis. Markers 2003,2004, 19, 229-238.
71. Koopmann, J., Zhang, Z., White, N., Rosenzweig, J. et al., Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 2004, 70, 860-868.
72. Mobley, J. A., Lau, L. Y., Pais, K. M, L'Esperance, V. M. et al., Monitoring the serological proteome: The latest modality in prostate cancer detection. J. Urol. 2004, 172, 331-337.
73. Yang, S.-J., Xiao, X.-Y., Zhang, W.-G., Zhang, L.-J. et al., Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005, 5, 83.
74. de la Fouchardière, C., Flechon, A., Droz, J.-P., Coagulopathy in prostate cancer. Neth. J. Med. 2003, 6, 347-354.
75. McKenzie, C. R., Eisenberg, P. R., in:Zahkari, S., Wassef, M. (Eds.), Alcohol and the Cardiovascular System, NIAAA Research Monograph #31, National Institutes of Health, Bethesda, MD, USA 1996, Vol. 31, pp. 413-440.
76. Schwegler, E. E., Cazares, L., Steel, L. F., Adam, B.-L. et al., SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005, 41, 634-642.
77. Hui, D. S. C., Chan, M. C. H., Wu, A. K., Ng, P. C., Severe acute respiratory syndrome (SARS): Epidemiology and clinical features. Postgrad. Med. J. 2004, 80, 373-381.
78. Collins, P. W., Machiavello, L. I., Lewis, S. J., Macartney, N. J. et al., Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br. J. Haematol. 2006, 735, 220-227.
79. Davis, M. T., Patterson, S. D., in: Bringmann, P., Butcher, E. C., Parry, G., Weiss, B. (Eds.), Systems Biology. Applications and Perspectives, Ernst Schering Research Foundation Workshop 61, Springer-Verlag, Heidelberg 2007, pp. 23-44.
80. Banks, R. E., Stanley, A. J., Cairns, D. A., Barrett, J. H. et al., Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 2005, 51, 1637-1649.
81. Drake, R. R., Cazarea, L. H., Corica, A., Malik, G. et al., Quality control, preparation, and protein stability issues for blood serum and plasma used in biomarker discovery and proteomic profiling assays. Bioprocess. J. 2004, 3, 45-50.
82. Semmes, O. J., Feng, Z., Adam, B.-L., Banez, L. L. et al., Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: 1. Assessment of platform reproducibility. Clin. Chem. 2005, 51, 102-112.
83. Diamandis, E. P., Peptidomics for cancer diagnosis: Present and future. J. Proteome Res. 2006, 5, 2079-2082.
84. Pang, R. T. K., Poon, T. C. W., Chan, K. C. A., Lee, N. L. S. et al., Serum amyloid A is not useful in the diagnosis of aevere acute respiratory syndrome. Clin. Chem. 2006, 52, 1202-1204.
85. Yu, M., Nardella, B. S., Pechet, L., Screening tests of disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis. Crit. Care Med. 2000, 28, 1777-1780.